Summary The high linear energy transfer, a-particle-emitting radionuclide astatine-211 (21'At) is of interest for certain therapeutic applications; however, because of the 55-to 70-jim path length of its a-particles, achieving homogeneous tracer distribution is critical. Hyperthermia may enhance the therapeutic efficacy of a-particle endoradiotherapy if it can improve tracer distribution. In this study, we have investigated whether hyperthermia increased the cytotoxicity of an 21'At-labelled monoclonal antibody (MAb) in tumour spheroids with a radius (approximately 100 gm) greater than the range of 21'At a-particles. Hyperthermia for 1 h at 420C was used because this treatment itself resulted in no regrowth delay. Radiolabelled chimeric MAb 81C6 reactive with the extracellular matrix antigen tenascin was added to spheroids grown from the D-247 MG human glioma cell line at activity concentrations ranging from 0.125 to 250 kBq ml-'. A significant regrowth delay was observed at 125 and 250 kBq ml-' in both hyperthermia-treated and untreated spheroids. For groups receiving hyperthermia, no increase in cytotoxicity was seen compared with normothermic controls at any activity concentration. These results and those from autoradiographs indicate that hyperthermia at 420C for 1 h had no significant effect on the uptake or distribution of this antitenascin MAb in D-247 MG spheroids.
The use of a-particle-emitting radionuclides for endoradiotherapy has several potential advantages compared with 1-emitters. The high linear energy transfer (LET) of a-particles makes them highly cytotoxic, rendering even hypoxic cells vulnerable. In addition, a-particles have relatively short effective path lengths in tissue, decreasing the radiation delivered to normal tissues located in close proximity to the tumour. For example, the mean path length of the a-particles emitted by 7.2-h half-life 21'At is 55-70 gm compared with 800 gm for the 5-particles emitted by '3'I (Gaze et al, 1992; . In contrast, the short a-particle range is potentially problematic because of the necessity for achieving homogeneous distribution of the radionuclide in the tumour for effective therapy. The limited range of a-particles has led investigators to focus therapeutic applications in which the tumour is present in thin sheets, such as neoplastic meningitis and peritoneal metastasis. The efficacy of 21'At-labelled monoclonal antibodies (MAbs) in a rat model of neoplastic meningitis has been encouraging .
Micrometastatic disease could offer another potential application of a-emitters if sufficiently homogeneous tracer distribution could be achieved. The determination of the most appropriate radionuclide for the treatment of small volume disease has been the focus of both experimental and theoretical studies (Humm and Cobb, 1990; Langmuir et al, 1990; 1992a) . If homogeneous distribution can be achieved, a-emitters such as 21'At yield a much than 1 cm diameter. In addition, specific targeting of radionuclide to cell membranes compared with a random distribution of decay sites within the tumour would offer the largest enhancement for 211At (Humm and Cobb, 1990) . For these reasons, targeted radiotherapy with a-particle emitters has potential for the treatment of micrometastatic disease.
Hyperthermia has been proposed as a technique for improving the homogeneity of the distribution of radiotherapeutics within solid tumours (Gridley et al, 1991 ). In the current study, we have investigated the effect of concurrent administration of hyperthermia at 42°C on the cytotoxicity of 21'At-labelled chimeric 81C6 MAb (ch8lC6) in spheroids grown from the D-247 MG human glioma line. These parameters were selected because previous studies have shown that hyperthermia at 42°C markedly enhanced the uptake of radioiodinated ch8lC6 in human glioma xenografts (Hauck et al, 1997) and because of the clinical interest in treating central nervous system malignancies with radiolabelled 81C6 MAb (Bigner et al, 1995) .
MATERIALS AND METHODS Cell line and spheroid propagation
The D-247 MG cell line, derived from a biopsy of a gliosarcoma, was established in the laboratory of Dr Darell Bigner and supplied by him for these studies (Bigner et al, 1988) . Before the initiation of these experiments, the cell line was demonstrated to be negative for mycoplasma by hybridization with a radiolabelled RNA probe for mycoplasma ribosomal RNA. Exponentially growing D-247 MG cells were harvested with 0.25% trypsin-0.02% EDTA and 753 viable cells were counted by trypan blue exclusion. RPMI-1640 medium (components purchased from JRH Biosciences, Lenexa, KS, USA) supplemented with 10% fetal calf serum, 2 mm L-glutamine, penicillin (50 U ml-') and streptomycin (50 jg ml-') was used for all experiments and hereafter is designated as complete medium. After determining their viability, 2 x 106 cells were added to 80 ml of complete medium in stirrer flasks at 30 r.p.m. and placed in an incubator at 37°C in a 5% carbon dioxide atmosphere. Spheroids were used in experiments 7 or 8 days after the start of the culture. Measurements of the surface area at the maximum diameter of each spheroid, made with the NIH image program, were used to calculate spheroid radius and volume. The spheroids used in the higher activity concentration experiment had an average radius of 103 ± 10 jm and an average volume of (4.69 ± 1.54) x 106 im3 at the start of the experiment.
Radiolabelled MAb
These experiments used the human/mouse chimeric construct of 8 1C6 (ch8 1C6) consisting of the human IgG2 constant regions and murine 81C6 variable regions. The construction, purification and characterization of ch8lC6, which reacts with the extracellular matrix antigen tenascin, has been described in a previous publication (He et al, 1994) . Astatine-211 was produced via the 209Bi(a,2n)2"'At reaction at the Duke University Medical Center cyclotron by irradiating bismuth metal targets with 28-MeV a-particles (Larsen et al, 1996) . The 21'At activity was isolated from the cyclotron target by dry distillation into chloroform.
N-succinimidyl 3-[21'At]astatobenzoate was synthesized, purified and coupled to ch8lC6 according to previously published procedures (Dangl et al, 1988) , as well as ch8lC6 were labelled with 1251 for the binding studies using a modification of the lodoGen method (Fraker and Speck, 1978 Binding of ch8l C6 to D-247 MG spheroids Aliquots of ten spheroids of similar diameter to those used in the cytotoxicity assays were individually selected on an inverted microscope and placed in Eppendorf tubes with Hepes-buffered complete medium. Because unlabelled ch81C6 was added to some groups in the cytotoxicity assay, a group of spheroids were incubated with unlabelled ch8lC6 at an about 40-fold excess for at least 1 h before the selection of spheroids for the binding analysis. This was carried out to determine the effect of the excess unlabelled MAb on binding of the radiolabelled ch8lC6. Non-specific uptake of radiolabelled MAb was also assessed. For analysis of the kinetics of MAb binding to spheroids, '251-labelled ch8lC6 or '25I-labelled TPS3.2 were added to a final concentration of 250 kBq ml-' and spheroids were placed on a rotator at 37 or 42°C. At selected time intervals (1, 2, 4, 8 and 24 h), spheroids were removed and the medium was aspirated and twice replaced with fresh medium to remove unbound MAb. Excess medium was aspirated, and the spheroids transferred to a clean tube for counting of bound radioactivity in a gamma-counter (1282 Compugamma, LKB Wallac, Tiirkii, Finland). All measurements were performed in triplicate.
To assess binding as a function of mAb activity concentration, aliquots of ten spheroids were incubated for 1 h at 37 or 42°C with 7.8-125 kBq ml-' of 125I-labelled MAb. The MAbs were labelled with 125I at the same specific activity as the 21'At-labelled MAb preparations used in the cytotoxicity assays to allow direct comparison between 125I-and 2"'At-labelled MAbs. Spheroids were washed, transferred to clean vials and bound activity counted in the gamma-counter. All samples were performed in triplicate. Counts per minute per spheroid were graphed as a function of activity concentration in the medium.
Spheroid growth inhibition assays
In some groups, unlabelled ch8lC6 was added to the spinner culture flask at protein concentrations ranging from 10 to 187.5 jig ml-' at least 1 h before the addition of 21'At-labelled ch8lC6. This was carried out to inhibit specific binding of the 2"'At-labelled ch8lC6 and thereby increase its penetration within the spheroid. These groups of spheroids, designated as low specific activity controls, contained at least an approximately 40-fold higher protein concentration of unlabelled MAb compared with the highest activity concentration of 211At-labelled ch81C6; at lower activity concentrations of radiolabelled MAb, this resulted in up to a 1000-fold excess of cold ch81C6.
A preliminary experiment was performed to determine a heating protocol that would not have a cytotoxic effect on these spheroids. As shown in Figure 1 , 1 h of heating at 42°C did not decrease the growth rate of the spheroids, whereas longer hyperthermia treatments inhibited spheroid regrowth. Samples (3 ml) of the spheroids suspended in complete medium were aliquoted into tubes, 2"lAt-labelled ch8 1C6 was added to the desired activity concentration (0.125 kBq ml-' to 250 kBq ml-'), and the volume adjusted to 4 ml. The low specific activity controls continued to have unlabelled ch8lC6 in the medium containing 2"'At-labelled ch8lC6.
Tubes were placed in an incubator at 37°C or 42°C on a rotator for 1 h. Then, the spheroids were washed twice using gravity sedimentation, resuspended in complete medium and placed in a sterile 15 x 60 mm Petri dish to select individual spheroids for plating. Gaze et al (1992) , spheroids were doses and/or longer incubation times, and to improve count rate at hosen and placed on soft agar (1.56%) overlaid with the conclusion of a 24-h study because of the longer half life of 1251. dium, one spheroid per well, using the centre eight
Even at an activity concentration of 250 kBq ml-', binding of 1251-vell plates. The outer wells were filled with distilled labelled ch81C6 to D-247 MG spheroids continued to increase over imize loss of medium by evaporation. Using a 20-pl 24 h, suggesting that antigen saturation had not occurred. After a pheroids per treatment group were selected. After 1-h incubation at 250 kBq ml-1, an activity concentration of 7.1 Bq urface area at the largest diameter of each spheroid per spheroid was reached. Binding of '25I-labelled ch8lC6 did not I using the NIH Image software program (v. 1.52), a vary with temperature over the first 2 h, after which at 420C it Ici personal computer and a Leitz microscope declined to the level reached by non-specific TPS3.2 MAb consiswith a digitizing camera (Sony Model XC-71 1) as tent with the compromised spheroid integrity at longer heating low. Spheroids were measured every other day for periods noted above. This study confmed that specific binding of ntil a 40-fold increase in volume was seen. (At larger ch8lC6 occurred by 1 h. Binding to spheroids as a function of spheroids began disintegrating.) Spheroids were fed medium activity concentration after a 1-h incubation is depicted in 200 gl of complete medium per well once a week. Figure 2 . The absolute percentage of medium activity bound to the spheroids was low. For example, with 250 and 125 kBq ml-' is ch81C6, 2.8 x 10-3% and 5.0 x 10-3% of the activity in the medium, area at the maximum diameter of the spheroid, respectively, was bound per spheroid at 370C. ng the NIH Image program (v. 1.52), was used to
The growth curves for D-247 MG spheroids incubated for 1 h radius and volume of each spheroid assuming spherwith 4-250 kBq ml-1 of 211At-labelled MAbs at 37 and 42°C, as r. The mean and standard deviation of the volume of well as those not exposed to labelled MAb, are presented in Figure  it group (n = 21-24 spheroids per group) was plotted 3. At 4 and 8 kBq ml-', no effect of 211At-labelled ch8lC6 on the treatment. The mean value of the spheroid volumes growth rate of D-247 MG spheroids was observed at either rather than the median because no spheroids were temperature. Incubation of spheroids with 125 and 250 kBq ml-' of is treatment protocol. Owing to contamination, only 211At-labelled ch8lC6 significantly delayed spheroid growth heroids, respectively, were measured at days 25 and compared with controls. Table 1 summarizes the number of days --plus-250 kBq ml-1 treatment group. Growth curves required for spheroids to achieve a 25-fold increase in volume for on semilog axes, and a second-order regression fit controls and groups incubated with 67.5, 125, and 250 kBq ml-' of nfidence interval was obtained using Sigma Plot 21'At-labelled ch8lC6. Similar trends were seen using a 30-fold tific, San Rafael, CA, USA). The time to reach a 25-increase in volume end point; however, these end points generally in volume was calculated, as well as the 95% confidid not occur on the linear portion of the growth curve and the 95% 1 for that time point. Previously published studies confidence intervals were very large. The initial volumes of the 1992) used a tenfold increase in volume as the end spheroids in these treatment groups were quite similar (Table 1) . er, because of the rapid growth rate of D-247 MG Correlation coefficients for the fit of the second-order regression ifold increase in volume in approximately 4-5 days), line ranged between 0.964 and 1.000. There was no significant n growth rate was seen at that end point. A 25-fold growth delay compared with 37°C controls for spheroid groups )lume was selected because that end point lay on the (a) incubated at 42°C; (b) preincubated with unlabelled ch8lC6 (low specific activity controls); and (c) groups treated with 67.5 kBq ml. None of the low specific activity control groups differed significantly from the temperature control groups. Exposure to 125 and 250kBq ml-' of 21'At-labelled ch8lC6 resulted in a significant growth delay when compared with their temperature and low specific activity control groups. However, at all activity concentrations, hyperthermia had no effect on the growth rate of the spheroids. Increasing the activity concentration from 125 to 250 kBq mr-' resulted in a significant increase in growth delay at both temperatures (Figure 3) . Autoradiographs (Figures 4 and 5) did not indicate that even prolonged heating (4 h) of the spheroids at 42°C increased MAb penetration.
DISCUSSION
Local hyperthermia can improve the absolute level of MAb taken up by tumours in vivo (Stickney et al, 1987; Cope et al, 1990; Hauck et al, 1997) . Although the mechanism by which hyperthermia exerts this effect is not known, alterations in MAb diffusion rate within the tumour interstitium as well as changes in antigen-MAb binding kinetics, vascular permeability and tumour blood flow all may play a role. Hyperthermia can enhance the cytotoxicity of low LET and low dose rate irradiation through inhibition of repair of radiation-induced damage and suppression of cell proliferation (Armour et al, 1991; Wang et al, 1992) . Thus, concurrent hyperthermia treatment could be useful not only for increasing the tumour uptake of MAbs labelled with ,B-emitting radionuclides but also for potentiating their cytotoxicity. Moreover, as investigated in the current study, hyperthermia might enhance the cytotoxicity of a-emitting endoradiotherapeutic agents by increasing the homogeneity of their tumour uptake.
Multicellular tumour spheroids offer a three-dimensional tumour model of micrometastatic disease (Walker et al, 1988; Langmuir et al, 1990; Mairs et al, 1991; Gaze et al, 1992) in which to investigate this possibility without the influence of variable vascular flow and permeability as well as elevated interstitial fluid pressure, all of which can influence the uptake of targeted therapeutic agents (Baxter and Jain, 1989) . There is disagreement concerning the penetration of MAbs into tumour spheroids. Both specific and non-specific MAbs have been reported to penetrate into the interior of spheroids within 6 to 11 h (McFadden and Kwok, 1988; Hjelstuen et al, 1996) . In contrast, it has been reported that intact MAbs targeted to cell membrane antigens bind only to the outer 1-3 cell layers of the spheroid, whereas MAb fragments penetrate 8-10 cell layers (Mairs et al, 1991) . Chen et al (1991) demonstrated that a MAb that binds to nuclear histones penetrates to the necrotic centre of spheroids, implying that the hindrance to homogeneous distribution is not inherently a consequence of the size of MAbs but rather a function of their binding to the first available antigen.
Spheroids are a valuable model for the evaluation of endoradiotherapeutics because they better represent the barriers to homogeneous distribution in micrometastatic nodules than monolayer cultures. In addition, because of their three-dimensional structure, spheroids are an excellent model for studying the effect of cross-fire on cell kill with radionuclides. A mathematical model of MAb diffusion through tumour tissue has demonstrated the importance of using a three-dimensional model for evaluating distribution issues (El-Karch et al, 1993) . By calculating the effect of interstitial components on diffusion, it was concluded that diffusion within a tumour nodule would be decreased by 10-to 20-fold compared with diffusion through water. The effects of impedance due to extracellular structures on the delivery of macromolecules must be addressed to investigate distribution on a cellular level. For these reasons, the tumour spheroid model was selected to investigate further the potential use of labelled MAbs in combination with hyperthermia, in particular as it might apply to the treatment of micrometastatic disease with 21'At-labelled MAbs. Although several investigators have achieved greater penetration of small molecules into spheroids by performing incubations under hypothermic conditions (Cody et al, 1993; Wartenberg and Acker, 1995) , these results probably are not germane to our attempt to use hyperthermia to achieve the same goal. In these studies, increased penetration of fluorescent dyes such as SNARF-1 into spheroids was accomplished by performing incubations at 8-10°C. However, this effect was not related to increased molecular diffusion; at room temperature, the dyes were being trapped in the outer spheroid layers because of degradation by esterases.
Concurrent administration of 1 h of hyperthermia at 42°C to the D-247 MG spheroids failed to enhance the cytotoxicity of 21'Atlabelled ch81C6. In interpreting these results, it is important to consider several of the mechanisms by which hyperthermia potentially might enhance the effectiveness of endoradiotherapy. Hyperthermia can enhance the cytotoxicity of low LET radiotherapy Figure 5 Autoradiograph of '251-labelled ch8l C6 distribution in a D-247 MG spheroid after a 4-h incubation at 420C taken at 250 x magnification. Section counterstained with haematoxylin and eosin through the inhibition of repair of sublethal damage; however, this should not be a factor with high LET a-particles such as those emitted by 211At (Gerner and Leith, 1977) . Hyperthermia can modulate cell membrane antigen expression (Wong et al, 1989; Davies and Lindmo, 1990) . Because ch8lC6 recognizes an extracellular matrix protein, tenascin, this may decrease the likelihood that hyperthermia modulated its expression; nonetheless, shedding might occur. Finally, hyperthermia might alter the kinetics of MAb-antigen interaction; however, we have demonstrated that the binding kinetics of 81 C6 to tenascin are the same over a temperature range of 37-450C (Hauck et al, 1996) .
Of particular relevance to the current study is the potential effect of hyperthermia on MAb diffusion through the tumour interstitium. The Stokes-Einstein equation for calculating the diffusion coefficient, D = RT/(NA6tcx), indicates that D is directly proportional to the temperature (Curry, 1984) . In addition, hyperthermia could decrease the viscosity of the interstitial fluid in the tumour (represented by in the above equation should increase its cytotoxicity in tumours with radii greater than the 55-70 jim range of 21'At a-particles. With 21 At-ch8lC6, binding to the spheroid surface would be expected to result in cell kill to a maximum depth of 70 gm. Given the 100-jim initial radius of these spheroids, cell killing at the centre of the spheroid would require diffusion of the MAb into the spheroid, a process that we had hoped would be facilitated by hyperthermia. Unfortunately, there was no evidence for improved MAb distribution within the spheroids by hyperthermia, either measured indirectly by growth delay or by direct visual inspection of spheroid autoradiographs. The effect of hyperthermia on MAb diffusion is complicated by the 'binding site barrier ' (van Osdol et al, 1991) with the consequence that high affinity MAbs bind to the first antigen encountered, thereby retarding its diffusion to the deeper layers of the tumour. This is consistent with observations of higher penetration of MAb into tumour spheroids with lower affinity MAbs or lower antigen concentrations (McFadden and Kwok, 1988; Langmuir et al, 1992b) . Because ch8lC6 has a high affinity for tenascin (KA approximately 1.4 x 109 M-1) (Hauck et al, 1996) , the binding site barrier may have impeded its penetration with the D-247 MG tenascin-positive spheroids. Hyperthermia did not exacerbate this barrier to penetration as increasing the incubation temperature from 37°C to 42°C does not have a significant effect on the association or disassociation rate constants, or the equilibrium constant for the binding of radioiodinated 81C6 to D-247 MG glioma cells in vitro (Hauck et al, 1996) .
Autoradiographs of these glioma spheroids exhibited patterns consistent with a binding-site barrier as binding of ch8lC6 was largely confined to the outer layers of the spheroids (Figures 4  and 5 ). Although autoradiographs of spheroids might have been used to directly measure alterations in the depth of MAb penetration from a 1-h hyperthermia treatment, measurements taken on a spheroid section that did not include the maximum diameter would overestimate depth of penetration. Moreover, as enhancing cytotoxicity was the practical goal of this study, we chose to use growth delay as the end point to assess the effect of hyperthermia on MAb distribution.
Experiments were performed using unlabelled MAb in an attempt to saturate outer layers of antigen and facilitate penetration of the labelled MAb into the spheroid. Intact MAb was selected as the blocking agent instead of monovalent Fab fragments for several reasons. The lower molecular weight and avidity of the Fab should facilitate its diffusion into inner spheroid regions; however, it is the outer regions of the spheroid in which blocking of labelled MAb binding is required. In addition, because the affinity of 8 1C6 Fab is more than tenfold lower than intact MAb (Hauck et al, 1996) , Fab bound to the outer spheroid layers would be a poor competitor for subsequently administered labelled intact MAb. Essand and colleagues (1995a,b) have demonstrated that increased penetration of labelled MAb into spheroids could be accomplished by previous administration of cold MAb. In DU 145 spheroids of about 800 jm diameter, this strategy increased labelled MAb delivery by about a factor of six at a penetration depth of 200 jim.
In the current study, no evidence for improved penetration of labelled MAb was seen either in the autoradiographs or in the growth delay experiments when spheroids were preincubated with an excess of cold MAb. In fact, the addition of unlabelled MAb had a deleterious effect as this tactic decreased growth delay in the 125 and 250 kBq ml-' groups. This presumably reflects competition of cold MAb for tenascin binding sites in outer spheroid layers. It is not clear why we were not able to improve spheroid penetration by blocking outer-layer binding with cold MAb. The amount of cold MAb that we used was at least 40 times higher than labelled MAb; the molar ratios of cold-labelled E4 MAb was 20:1 in one study (Essand et al, 1995a) and not indicated in the other (Essand et al, 1995b) . Differences between our conditions and those of Essand et al (1995a,b) that might be relevant include our use of smaller spheroids (200 ,um v 800 ,um) and the fact that the 81C6 MAb reacts with a highly expressed, extracellular matrix antigen, whereas E4 binds to a cell surface antigen.
In summary, this study has demonstrated that a 1 h, 42°C hyperthermia treatment does not significantly improve cytotoxicity of 21'At-labelled ch8lC6 MAb in glioma spheroids as measured by spheroid growth delay. Longer hyperthermia treatments that enhance MAb uptake in vivo, such as 4 h at 41.8°C (Hauck et al, 1997) , may still have a positive effect on the distribution of MAbs and, possibly, their cytotoxicity in vivo; however, the deleterious effects of prolonged hyperthermia treatment itself for these human glioma spheroids prevented the testing of these conditions in this in vitro model. Nonetheless, the significantly enhanced MAb tumour uptake and tumour-to-normal-tissue ratios obtained with hyperthermia in xenograft models suggests there may be a place for hyperthermia/labelled MAb combination therapy in the clinical armamentarium for cancer treatment. However, further studies are needed to better define the critical mechanisms responsible for hyperthermic enhancement of mAb uptake and cytotoxicity, as well as the optimal radionuclide for combining hyperthermia with radioimmunotherapy.
